Myriad Genetics, Inc. Submits Supplementary Premarket Approval Application to U.S. Food and Drug Administration for its BRACAnalysis CDx Test

Myriad Genetics, Inc. announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis CDx test as a companion diagnostic to AstraZeneca’s and Merck’s PARP inhibitor Lynparza (olaparib) for men with metastatic castration-resistant prostate cancer.